Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

Psychopharmacology
Ryosuke ArakawaTetsuya Suhara

Abstract

Paliperidone ER is a novel antipsychotic drug in an extended-release (ER) formulation. As with all antipsychotics, careful dose setting is necessary to avoid side effects. In this study, we measured striatal and extrastriatal dopamine D2 receptor occupancy during paliperidone ER treatment in patients with schizophrenia using positron emission tomography (PET) to compare regional occupancy and to estimate the optimal dose. Thirteen male patients with schizophrenia participated in this 6-week multiple-dose study. Six of them took 3 mg of paliperidone ER per day, four took 9 mg, and three took 15 mg. Two to 6 weeks after first drug intake, two PET scans, one with [11C]raclopride and one with [11C]FLB 457, were performed in each patient on the same day. The relationship between the dose or plasma concentration of paliperidone and dopamine D2 receptor occupancy was calculated. The dopamine D2 receptor occupancies in the striatum measured with [11C]raclopride and the temporal cortex measured with [11C]FLB 457 were 54.2-85.5% and 34.5-87.3%, respectively. ED50 values of the striatum and temporal cortex were 2.38 and 2.84 mg/day, respectively. There was no significant difference in dopamine D2 receptor occupancy between the striatum an...Continue Reading

References

Feb 1, 1995·The American Journal of Psychiatry·S NybergL Bertilsson
Aug 16, 1997·Lancet·Lyn S PilowskyR W Kerwin
Dec 1, 1996·NeuroImage·Adriaan A Lammertsma, S P Hume
Jun 5, 1998·Trends in Pharmacological Sciences·M S LidowP S Goldman-Rakic
Nov 4, 2000·The British Journal of Psychiatry : the Journal of Mental Science·C M StephensonLyn S Pilowsky
Apr 3, 2001·The International Journal of Neuropsychopharmacology·Tetsuya SuharaLars Farde
Apr 9, 2001·Psychopharmacology·Fumihiko YasunoShuji Tanada
Dec 4, 2001·The British Journal of Psychiatry : the Journal of Mental Science·X XiberasM L Paillère-Martinot
Dec 12, 2001·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Jacques DelforgeA Syrota
Jan 12, 2002·Archives of General Psychiatry·Tetsuya SuharaLars Farde
Jan 25, 2003·Journal of Clinical Psychopharmacology·Rodrigo A BressanLyn S Pilowsky
Nov 8, 2003·The International Journal of Neuropsychopharmacology·Mirjam TalvikLars Farde
Feb 7, 2004·The International Journal of Neuropsychopharmacology·Akihiro TakanoYoshiro Okubo
Feb 16, 2005·The International Journal of Neuropsychopharmacology·Ola GefvertSvante Nyberg
Jul 26, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Akihiro TakanoTsukasa Koyama
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert M KesslerHerbert Y Meltzer
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gerhard GründerPeter Bartenstein
Nov 18, 2005·The International Journal of Neuropsychopharmacology·Akihiro TakanoYoshiro Okubo
Mar 4, 2006·The American Journal of Psychiatry·Gary RemingtonShitij Kapur
Jun 2, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert M KesslerHerbert Y Meltzer
Nov 2, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ofer AgidShitij Kapur
May 24, 2007·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Robert B InnisRichard E Carson

Citations

Jan 5, 2012·The Journal of Pharmacology and Experimental Therapeutics·E C MulyL L Howell
Mar 31, 2011·Drug Design, Development and Therapy·Maximilian GahrRoland W Freudenmann
Dec 12, 2013·Biomarkers in Medicine·Brett A EnglishLarry Ereshefsky
Apr 3, 2014·Annals of General Psychiatry·Joseph PeuskensAndreas Schreiner
Apr 2, 2010·European Journal of Clinical Pharmacology·Yasmin NazirizadehChristoph Hiemke
Dec 15, 2012·Expert Review of Neurotherapeutics·Pierre S ChueGlen B Baker
Apr 23, 2013·Expert Opinion on Drug Metabolism & Toxicology·Victor A VoicuFlavian Ştefan Rădulescu
Aug 1, 2009·Expert Opinion on Drug Discovery·Gianluca NucciItalo Poggesi
Sep 16, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Victor A VoicuDalia Simona Miron
Jan 1, 2016·Pharmaceutical Research·Martin JohnsonJohannes H Proost
Sep 28, 2010·Nuclear Medicine and Biology·Kazuhiko YanamotoMing-Rong Zhang
Jul 31, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·G MarcheseL Pani
Apr 28, 2011·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Euitae KimJun Soo Kwon
Nov 18, 2008·Journal of Psychiatric and Mental Health Nursing·A Jones
Oct 1, 2008·Pharmacotherapy·Jehan Marino, Joshua Caballero
Jan 26, 2010·NeuroImage·Lisbeth MarnerGitte M Knudsen
Apr 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Mizuho SekineTetsuya Suhara
Jun 28, 2016·Expert Opinion on Drug Safety·L OrsoliniD De Berardis
Feb 1, 2017·Expert Opinion on Drug Safety·Massimo Carlo MauriAlfredo Carlo Altamura
Apr 30, 2017·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Yin CuiYoung-Chul Chung
Jan 1, 2011·Journal of Central Nervous System Disease·Edoardo Spina, Rosalia Crupi
May 20, 2018·Expert Review of Clinical Pharmacology·Georgios SchoretsanitisJose de Leon
Apr 22, 2008·The Cochrane Database of Systematic Reviews·A Nussbaum, T S Stroup
Jun 23, 2011·Journal of Clinical Psychopharmacology·Hiroyuki UchidaDavid C Mamo
Oct 24, 2009·European Archives of Psychiatry and Clinical Neuroscience·Ryosuke ArakawaTetsuya Suhara
Jun 24, 2010·Drugs·Claudine M Chwieduk, Gillian M Keating
May 29, 2020·Neuropsychopharmacology Reports·Ryosuke ArakawaChrister Halldin
Dec 17, 2010·Expert Review of Neurotherapeutics·Nora S VyasBasant K Puri
Feb 27, 2013·Psychiatry and Clinical Neurosciences·Hidenobu SuzukiKatsunaka Mikami
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura

Related Concepts

FLB 457, hydrobromide, (S)-isomer
Paliperidone
Brain Chemistry
Data Interpretation, Statistical
Depot Preparations
Dose-Response Relationship, Drug
Isoxazoles
Factor Construct Rating Scales (Fcrs)
Pyrimidines
Pyrrolidines

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here